Here you will find the Funding Position of CCG Commissioned High-Cost Drugs within the Lancashire and South Cumbria Health Economy
A number of High-Cost Drugs, devices, procedures and products have been excluded from the scope of the national tariff of Payment by Results. These are listed on tab 13b of the following document:
2024/25 Annex A: The national tariff workbook
High-cost drugs are commissioned by:
The funding position of medicines directly commissioned by NHS England can be accessed via the NHS England website
Refer to the Manual for Prescribed Specialised Services for further information about prescribed specialised services, some of which are directly commissioned by NHS England and some by CCGs.
Date Posted: 14 - Nov - 2022
Approval Mechanism:
Date Posted: 22 - Oct - 2024
Approval Mechanism: Blueteq
Date Posted: 16 - Jun - 2023
Approval Mechanism:
Date Posted: 01 - Dec - 2018
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 15 - Feb - 2023
Approval Mechanism: Blueteq form
Date Posted: 20 - Jul - 2023
Approval Mechanism: Blueteq
Date Posted: 13 - Jul - 2020
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 01 - Sep - 2017
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 29 - Nov - 2019
Approval Mechanism: Prior Approval Blueteq Form Available
Use in high-risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.
Date Posted: 01 - Jan - 2015
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 01 - May - 2016
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 29 - Nov - 2019
Approval Mechanism: N/A
Prevention of recurrence of ulcerative colitis following surgery.
